Allogene Therapeutics Inc (ALLO)vsRevolution Medicines Inc (RVMD)
ALLO
Allogene Therapeutics Inc
$1.78
+1.14%
HEALTHCARE · Cap: $608.06M
RVMD
Revolution Medicines Inc
$203.77
+0.21%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Allogene Therapeutics Inc generates 525% more annual revenue ($4.64M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. ALLO earns a higher WallStSmart Score of 28/100 (F).
ALLO
Avoid28
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 16.8x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALLO
The strongest argument for ALLO centers on Price/Book, Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : ALLO
The primary concerns for ALLO are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
RVMD is growing revenue faster at -95.2% — sustainability is the question.
ALLO generates stronger free cash flow (-32M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALLO scores higher overall (28/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Allogene Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?